Insider Selling: Alexion Pharmaceuticals, Inc. (ALXN) EVP Sells $445,045.02 in Stock

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) EVP John B. Moriarty sold 3,538 shares of the business’s stock in a transaction on Tuesday, February 7th. The shares were sold at an average price of $125.79, for a total transaction of $445,045.02. Following the transaction, the executive vice president now owns 46,801 shares in the company, valued at approximately $5,887,097.79. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 126.51 on Monday. Alexion Pharmaceuticals, Inc. has a 12 month low of $109.12 and a 12 month high of $162.00. The company has a market cap of $28.33 billion, a price-to-earnings ratio of 77.14 and a beta of 1.39. The firm’s 50-day moving average is $131.00 and its 200-day moving average is $127.05.

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

COPYRIGHT VIOLATION WARNING: This report was originally posted by sleekmoney and is the sole property of of sleekmoney. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this report can be viewed at http://sleekmoney.com/insider-selling-alexion-pharmaceuticals-inc-alxn-evp-sells-445045-02-in-stock/1657621.html.

A number of research analysts recently issued reports on ALXN shares. FBR & Co reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Monday, November 14th. Vetr downgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $107.00 target price on the stock. in a research report on Tuesday, October 18th. Oppenheimer Holdings, Inc. started coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, December 15th. They set a “market perform” rating on the stock. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 28th. Finally, Credit Suisse Group restated an “outperform” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Friday, December 16th. Seven investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $170.70.

Several institutional investors have recently bought and sold shares of ALXN. Bank of The West raised its position in Alexion Pharmaceuticals by 9.0% in the second quarter. Bank of The West now owns 43,444 shares of the biopharmaceutical company’s stock valued at $5,073,000 after buying an additional 3,585 shares in the last quarter. Regal Investment Advisors LLC bought a new position in Alexion Pharmaceuticals during the second quarter valued at about $2,764,000. Princeton Alpha Management LP bought a new position in Alexion Pharmaceuticals during the second quarter valued at about $3,242,000. Granite Point Capital Management L.P. bought a new position in Alexion Pharmaceuticals during the second quarter valued at about $1,168,000. Finally, Exane Asset Management bought a new position in Alexion Pharmaceuticals during the second quarter valued at about $16,516,000. 94.98% of the stock is owned by hedge funds and other institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/insider-selling-alexion-pharmaceuticals-inc-alxn-evp-sells-445045-02-in-stock/1657621.html

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *